Cardio Diagnostics Holdings, Inc. (CDIO) AI Stock Analysis
CDIO AI stock analysis summary
AI ResearchCardio Diagnostics Holdings, Inc. (CDIO) is a clinical-stage biotechnology company developing epigenetics-based tests for cardiovascular disease. The company generated $14,450 in trailing twelve-month revenue through June 30, 2026, alongside a net loss of -$6.5M in FY2025. With a market capitalization of $5.0M, CDIO maintains $5.6M in cash and short-term investments.
- Market cap
- $5.0M
- Revenue (TTM)
- $14,450
- P/E
- —
- 1Y return
- -61.0% S&P 500 16.8%
- Avg. target
- $60.00 3450.3% vs last close
Bull case
- The company maintains a solid liquidity cushion with $5.6M in cash and short-term investments against only $369,698 in total debt as of June 30, 2026.
- Wall Street analysts maintain a mean price target of $60.00, representing a 3450.3% premium to the last closing price of $1.69.
- Gross margins have held steady at 100.0% across each reported fiscal year from FY2021 through FY2025.
Bear case
- Revenue fell 57.5% in FY2025 to $14,825 and further contracted 28.3% year-over-year in the quarter ended June 30, 2026.
- Operating losses remain severe, evidenced by a trailing twelve-month operating margin of -27950.5% and FY2025 net income of -$6.5M.
- The stock has lagged broader benchmarks significantly, falling 61.0% over the past year while the S&P 500 gained 16.8%.
What Cardio Diagnostics does
Cardio Diagnostics Holdings, Inc., headquartered in Chicago, Illinois, specializes in the development and commercialization of epigenetics-based clinical tests tailored for cardiovascular disease. Founded in 2017, the company aims to advance precision medicine in cardiovascular health. Its flagship product, Epi+Gen, is a three-year symptomatic coronary heart disease (CHD) risk assessment test designed to predict and prevent CHD events, such as heart attacks. The company's innovative diagnostic solutions are designed to provide healthcare professionals and patients with reliable tools for early detection and personalized management of CHD risks through continued research and development.
Growth and profitability
Cardio Diagnostics recorded revenue of $901 in FY2021, which grew to $950 in FY2022 and $17,065 in FY2023. Revenue peaked at $34,890 in FY2024 before falling 57.5% to $14,825 in FY2025. Across FY2021 through FY2025, gross margin remained at 100.0%. However, substantial operating costs resulted in net losses of -$620,448 in FY2021, -$4.7M in FY2022, -$8.4M in FY2023, -$8.4M in FY2024, and -$6.5M in FY2025, with R&D expense rising to $641,212 in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $14,450, with quarterly revenue growth down 28.3% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Cardio Diagnostics held $5.6M in cash and short-term investments against total debt of $369,698, resulting in net cash of $5.2M. Total assets were $7.9M and shareholders' equity was $7.4M. The company reported a current ratio of 17.15 and a debt-to-equity ratio of 0.05. In FY2025, operating cash flow was -$5.7M, free cash flow was -$5.9M, and capital expenditures were $187,317, while share count dropped 63.6% over five years.
Valuation and performance
Cardio Diagnostics traded at $1.69 as of October 16, 2026, reflecting a 1-year return of -61.0% compared to a 16.8% gain for the S&P 500 (SPY). The company has an enterprise value of $465,181 and a market cap of $5.0M. Its price-to-sales ratio is 346.1x, significantly higher than the 4.1x median of its US-listed Healthcare peers. The EV to revenue ratio stands at 32.2x, and price-to-book is 0.8x. The stock has a beta of 2.24.
What analysts expect
Wall Street analysts have set a mean price target of $60.00 for CDIO, which is 3450.3% above its last close of $1.69. For the next fiscal year, consensus estimates project an EPS of $0.00 and revenue of $0. Over the last four quarters, Cardio Diagnostics beat earnings per share estimates 1 time. The company's next earnings report is scheduled for November 11, 2026.
Key risks and what to watch
- Cash burn is high relative to revenue, with free cash flow of -$5.9M in FY2025 compared to $5.6M in cash reserves.
- Revenue generation remains minimal at $14,450 over the trailing twelve months, reflecting commercialization challenges.
- Share price volatility is elevated, as shown by a beta of 2.24 and a 52-week trading range spanning from $0.97 to $7.91.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this CDIO AI stock analysis
This page is an AI-written research summary of Cardio Diagnostics Holdings, Inc. (CDIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: CDIO income statement, CDIO balance sheet, CDIO key metrics, CDIO analyst forecast, CDIO chart. See the CDIO stock overview for the latest quote and news.
CDIO AI stock analysis FAQ
What is Cardio Diagnostics Holdings' core product?
The company's flagship product is Epi+Gen, a three-year symptomatic coronary heart disease risk assessment test designed to predict and prevent heart attacks.
How much cash does Cardio Diagnostics hold?
As of June 30, 2026, Cardio Diagnostics held $5.6M in cash and short-term investments, with total debt of $369,698.
What is the consensus analyst price target for CDIO stock?
Analysts have a mean price target of $60.00, which sits 3450.3% above its October 16, 2026 closing price of $1.69.
When is Cardio Diagnostics' next earnings announcement?
The company's next scheduled earnings date is November 11, 2026.